News

Article

USP Submits Comments to FDA on Biologics Naming Guidance

USP responds to FDA's draft guidance on the naming of biological products.

USP Submits Comments to FDA on Biologics Naming Guidance

The United States Pharmacopeial Convention (USP) has submitted its

to FDA regarding Draft Guidance, Nonproprietary Naming of Biological Products: Guidance for Industry, which details FDA’s biologic naming proposal. FDA has proposed that all biological products have a nonproprietary name that includes a manufacturer-specific FDA-designated suffix.

 “We understand the naming approach for biologics in the Draft Guidance reflects FDA’s interest in preventing inadvertent substitution of and facilitating pharmacovigilance for biological products,” said Jaap Venema, PhD, executive vice-president and chief science officer of USP, in a press release. “At the same time, USP believes it is critically important to maintain a uniform and scientifically-based approach that does not create unintended risks for patients and practitioners, and encourages FDA to consider alternative solutions to reach its goals.”

In their comments, USP states, “the existing scientifically-based nonproprietary naming system for biologics and other drugs has served patients and practitioners well for over a century. The naming approach proposed in the Draft Guidance represents a departure from well-established scientific naming principles and could have unintended negative consequences; and while USP shares FDA’s goal of improving safe medication use, USP encourages FDA to consider alternative solutions to achieve this goal.”   

USP plans on commenting separately to FDA’s Proposed Rule, “Designation of Official Names and Proper Names for Certain Biological Products,” which provides proposed names for six products based on the naming convention outlined in the draft guidance. 

Source: USP

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content